The compound is derived from an actinomycete of the Streptomyces genus.
It is remarkable amongst cytotoxic agents for the absence of nitrogen from its structure. The drug is supplied in vials containing 2*5 mg. of the pure crystalline material, and to reduce decomposition to the minimum, these vials must be kept in cold storage and darkness at -10°C. until immediately before use.
Selection of patients
The first trial of Mithramycin in the United Kingdom has been devoted to a wide range of cases of advanced nmalignancy, the majority of which had had previous therapy. The range of tumour types studied is shown in Table I , the age range in Table II and in the histogram in Fig. 1 , and the extent of previous therapy amongst the patients in the series in Table III. *Present address: The Royal Infirmary, Glasgow, C4. Thirteen confirmed and separate primary sites and an unknown primary site were selected, from all of which a definitely invasive malignant spread had occurred. The histopathological features in these cases were varied enough to ensure a broad survey for therapeutic activity of the drug.
The youngest patient in the series was 35 years of age and the oldest was 81 years, but inspection of Table II and the histogram in Fig. 1 reveals that the majority (16) were under 60 years, and there is also a large proportion under the age of 50 years (10 cases). Table IV .
Of the 26 patients who were treated with Mithramycin, the majority (16 cases) showed no improvement either immediately or during the follow-up period of the survivors. In this group, the tumours remained unaltered in size or increased, fresh metastases were discovered, there was failure to gain weight or there was no improvement in the performance status (Karnofsky et al., 1951) . Six patients benefited by a temporary arrest of their disease, but there was recurrence of the disease in all cases in under 1 month following cessation of therapy. However, at the time of writing (January, 1966), 4 of the 26 patients undergoing trial have slhown a definite quantitative remission.
Within 1 month of commencing treatment, 7 patients had died of their disease, 1 patient died during the course of treatment but from causes other than could be ascribed to drug toxicity, and 1 patient died of congestive cardiac failure although in at least temporary remission following treatment with Mithramycin.
Of the patients considered to have a temporary remission of their disease, all were given a specified maximum total dose of 2.0 mg. per kilogram body weight. All had extensive metastases and had not responded to previous surgery, radiotherapy or cytotoxic agents. These cases included primary malignant changes in the colon, pancreas, testis, ovary and included adenocarcinoma, anaplastic carcinoma, seminoma and leiomyosarcoma cell types.
Definite quantitative remission occurred in 4 of the 26 patients in the trial. One had an anaplastic invasive carcinoma of the breast, the second an adenocarcinoma of the rectum, the third a poorly differentiated cystadenocarcinoma of the ovary and the last had extensive metastases from a malignant melanoma originating in the choroid. However, it must be specifically emphasised that our period of follow-up of these patients is necessarily short and it is, of course, impossible to forecast for how long the remission in this last group of patients will be maintained. Comments have already been made on side effects in connection with the plan and execution of therapy for this trial. Seventeen patients suffered from nausea, 12 of whom required therapeutic control, but only 5 progressed to troublesome vomiting necessitating more rigorous treatment than administration of phenothiazone compounds. An unexpected accompaniment of Mithramycin administration was dizziness and headache, which responded poorly to analgesics and antihistamines: one patient had several epileptic fits but was found at autopsy to have multiple cerebral metastases. In only 2 patients were side effects severe enough to demand temporary cessation of the trial. and only 1 patient did not complete the course of Mithramycin therapy from choice. Anorexia occurred in 4 patients, all of whom were cachectic before treatment was commenced.
Apart from 1 instance of leucopenia and one of relative thrombocytopenia, there were no serious adverse effects on erythropoeiesis, leucopoeiesis or the coagulating factors, nor were adverse effects on liver function discovered.
DISCUSSION
The present position of cytotoxic agents in the treatment of malignant disease is controversial. Both clinicians and laboratory workers are more aware of the complexity of the problem and would appear to accept the fact that these agents are still in the experimental stage as regards the control of neoplastic changes in man. Particular aspects of this problem are fully discussed by Davis (1965) .
The closest co-operation between the laboratory and the ward cannot be too fully stressed, and this is particularly important when new agents which show promise from laboratory testing are investigated for their clinical effects. Carefully controlled animal experiments must be followed by equally carefully controlled clinical trials. In this respect, the phasing of clinical trials as discussed in the World Health Organization Technical Report No. 232 (1962) is logical in its concept and is reasonably practicable in its application.
The clinical pharmacology of Mithramycin was reported by Curreri and Ansfield (1960) , but these authors did not discuss in detail some haematological factors of importance, although they did stress that thrombocytopenia occurred when not expected from the results of animal experiments. Later, clinical assessment for spectrum of activity by Parker, Wiltsie and Jackson (1960) suggested that the range of usefulness of Mithramycin was overshadowed by its toxicity. Such toxicity was most likely due to their method of administration in single calculated daily intravenous doses. Kofman (1963) points out that a reduction in dose rate and the use of continuous intravenous infusion mitigates toxicity, reduces side effects and broadens the spectrum of activity. Even so, careful assessment of the reports by Kofman and Ream (1963) , Spear (1963) , and Kofman, Medrek and Alexander (1964) shows that very few cell types and even fewer sites of primary growth are susceptible to cytotoxic activity when treated with Mithramycin. In fact, the only cases in which unequivocal remission has occurred are those of malignant disease of the testis and ovary, which is supported by the trials conducted by Brown and Kennedy (1965) .
As outlined above, we have conducted a first trial in the United Kingdom of Mithramycin for its effect on advanced malignant disease. Our results from this trial show that the spectrum of activity of this drug is limited amongst the different cell types studied and the primary sites represented in this series. Quantitative or even temporary remission was confined to a small proportion of the cases selected for study (up to the time of writing). These included cases of malignant changes in both the testis and the ovary and would certainly support the findings of Kofman, Medrek and Alexander (1964) and those of Brown and Kennedy (1965) ; our impression, therefore, is that Mithramycin may have some specific and beneficial effect on neoplastic changes arising in reproductive tissue. However, we are fully aware that all our patients were in an advanced stage of their disease; the fact that there had been little or no response to previous therapy was a fair indication that dramatic response to yet another cytotoxic agent was only a remote possibility.
The absence of overwhelming toxicity from the drug may indicate insufficient dosage, but the reports of others suggest that our daily dose was as high as possible, compatible with the very narrow effective therapeutic range of the drug. It has been suggested that final therapeutic effect may be delayed for many weeks and that remission can only be maintained by further courses of the drug. There is, therefore, the possibility that in some of the cases where temporary remission occurred, further courses of the drug may have had a more quantitative and lasting effect. Our preliminary investigations would indicate that further trials using more prolonged and repeated courses in patients showing response should be performed.
